PURPOSE: The aim of this study was to report outcomes of type I Boston keratoprosthesis (KPro) as primary corneal surgery in nonautoimmune corneal disorders. METHODS: In this retrospective, observational, large single-center case series of 43 eyes (37 patients) that were followed for an average of 39 months (1-6 years), primary implantation of the type I Boston KPro was performed in all patients. Visual acuity at year 1, visual acuity at last follow-up, and postoperative complication rates were examined for all eyes. RESULTS: Preoperative best-corrected visual acuity ranged from 20/60 to light perception, with vision of 20/200 or worse in 88%. Vision was ≥20/200 at 1 year in 77% of eyes (P < 0.0001). Complications included retroprosthetic membrane formation (51%), glaucoma progression (47%), corneal melt (19%), and sterile vitritis (14%). CONCLUSIONS: In a large series with long follow-up, primary Boston KPro effectively restored vision. Close follow-up is needed to manage the known complications after Boston KPro.
PURPOSE: The aim of this study was to report outcomes of type I Boston keratoprosthesis (KPro) as primary corneal surgery in nonautoimmune corneal disorders. METHODS: In this retrospective, observational, large single-center case series of 43 eyes (37 patients) that were followed for an average of 39 months (1-6 years), primary implantation of the type I Boston KPro was performed in all patients. Visual acuity at year 1, visual acuity at last follow-up, and postoperative complication rates were examined for all eyes. RESULTS: Preoperative best-corrected visual acuity ranged from 20/60 to light perception, with vision of 20/200 or worse in 88%. Vision was ≥20/200 at 1 year in 77% of eyes (P < 0.0001). Complications included retroprosthetic membrane formation (51%), glaucoma progression (47%), corneal melt (19%), and sterile vitritis (14%). CONCLUSIONS: In a large series with long follow-up, primary Boston KPro effectively restored vision. Close follow-up is needed to manage the known complications after Boston KPro.
Authors: Ghasem Yazdanpanah; Kelley J Bohm; Omar M Hassan; Faris I Karas; Abdelrahman M Elhusseiny; Manachai Nonpassopon; Muanploy Niparugs; Elmer Y Tu; Joel Sugar; Mark I Rosenblatt; Maria S Cortina; Ali R Djalilian Journal: Am J Ophthalmol Date: 2019-11-12 Impact factor: 5.258
Authors: Mohsin H Ali; Mark S Dikopf; Anthony G Finder; Ahmad A Aref; Thasarat Vajaranant; Jose de la Cruz; Maria Soledad Cortina Journal: Cornea Date: 2018-05 Impact factor: 2.651
Authors: Albert Santos; Luzia Diegues Silva; Luciene Barbosa de Sousa; Denise de Freitas; Lauro Augusto de Oliveira Journal: Am J Ophthalmol Case Rep Date: 2017-03-14
Authors: Kai B Kang; Faris I Karas; Ruju Rai; Joelle A Hallak; Joann J Kang; Jose de la Cruz; Maria S Cortina Journal: PLoS One Date: 2018-02-06 Impact factor: 3.240